Related Experiment Video
Updated: Jul 9, 2026
Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens
Published on: December 9, 2022
Multicystic peritoneal mesothelioma mimicking recurrent pseudomyxoma peritonei
Alessia Scarton1, Marco Tonello1, Elisa Pizzolato1
1Surgical Oncology Department, Unit of Surgical Oncology of Digestive Tract, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Abstract:
Multicystic peritoneal mesothelioma (MCPM) is a borderline variant of peritoneal mesothelioma with indolent behaviour but a significant recurrence rate without radical treatment. Due to its rarity, risk factors and optimal treatment are still to clarify. The present clinical case is a report of MCPM developed after laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (Lap CRS-HIPEC) for pseudomyxoma peritonei (PMP) of appendiceal origin. The patient was treated for PMP with Lap CRS-HIPEC. One year later a recurrence was suspected at the thorax-abdomen computed tomography scan. After multidisciplinary discussion, she underwent iterative Lap CRS-HIPEC. Pathological examinations revealed MCPM. After 3 years of follow-up the patient is disease-free for both tumours. This is a unique case of MCPM mimicking recurrent PMP. Lap CRS-HIPEC is an effective approach for both conditions.
Insights
Multicystic peritoneal mesothelioma (MCPM) is rare and can mimic pseudomyxoma peritonei (PMP) recurrence. Iterative laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (Lap CRS-HIPEC) proved effective for both conditions in this unique case.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Background:
- Multicystic peritoneal mesothelioma (MCPM) is a rare borderline tumor with indolent behavior but high recurrence rates.
- Optimal treatment and risk factors for MCPM remain unclear due to its rarity.
- Pseudomyxoma peritonei (PMP) of appendiceal origin is often treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC).
